𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms

✍ Scribed by Takahide Taniguchi; Satsuki Sumitani; Michitaka Aono; Junichi Iga; Sawako Kinouchi; Hirosi Aki; Mami Matsushita; Kyoko Taniguchi; Mami Tsuno; Kazunari Yamanishi; Masahito Tomotake; Yasuhiro Kaneda; Tetsuro Ohmori


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
91 KB
Volume
21
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Replacement of antipsychotic drugs with quetiapine (QTP) was tried in a naturalistic setting in chronic schizophrenic patients who still showed moderate psychiatric symptoms and either showed extrapyramidal symptoms (EPS) or took anti‐parkinson drugs for the EPS. QTP was added on and gradually increased while the previous drugs were tapered and discontinued whenever possible. Clinical symptoms, objective and subjective QOL, and EPS were measured before and 6 months after QTP addition, using Brief Psychiatric Rating Scale (BPRS), Quality of Life Scale (QLS), Schizophrenia Quality of Life Scale (SQLS) and Drug‐Induced Extrapyramidal Symptom Scale (DIEPSS), respectively. Twenty‐one patients completed the trial and received the assessment. It was found that replacement with QTP‐improved clinical symptoms, objective and subjective QOL and EPS. This improvement was equally observed in not only patients who switched to QTP monotherapy (n = 11) but also patients who took QTP together with reduced small doses (4.4 ± 4.3 mg/day) of previous drugs (n = 11). The results suggest that replacement with QTP improves symptoms as well as objective and subjective QOL in a subgroup of schizophrenia. Copyright Β© 2006 John Wiley & Sons, Ltd.


πŸ“œ SIMILAR VOLUMES


An analysis of safety and tolerability d
✍ Kristina Timdahl; Anders Carlsson; GΓΆran Stening πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 204 KB πŸ‘ 1 views

## Abstract ## Aim This analysis evaluated the tolerability profile of quetiapine using data from all comparative controlled studies in patients with schizophrenia or related disorders in the AstraZeneca clinical trials database, focusing on extrapyramidal symptoms (EPS). ## Methods Adverse even

Age and anxiety and depressive symptoms:
✍ Patrick J. Brown; Steven P. Roose πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 330 KB πŸ‘ 1 views

## Abstract ## Objectives The present study investigated whether anxiety and depressive symptomatology moderates the relationship between age and quality of life. ## Methods The study was a community‐based survey using mailed questionnaires conducted within the Department of Psychology at Washin

Quetiapine is effective against anxiety
✍ Siegfried Kasper πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 75 KB πŸ‘ 2 views

This analysis of data from the open-label extension (OLE) phases of three randomized clinical trials of quetiapine in patients with schizophrenia (n=415) was undertaken to investigate whether the initial improvements in anxiety and depressive symptoms were maintained during long-term treatment. The

Quetiapine versus olanzapine for the tre
✍ Pinkhas Sirota; Irit Pannet; Ady Koren; Eleonora Tchernichovsky πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 2 views

## Abstract Negative symptoms are considered the most debilitating and refractory aspect of schizophrenia, being associated with poor social, occupational and global outcomes. Conventional antipsychotics have limited efficacy against these symptoms and poor tolerability profiles. Atypical antipsych